Don, nothing like a little exaggeration in your characterization of the 'shorts' position. I can't recall anyone calling ENMD a scam or crooked. Nor do I recall anyone saying it was headed straight for bankruptcy. It's hard to have a rational conversation if the sides split into factions and hunker down on their opinions.
The stock is speculative, and will continue to swing based on hopes and dreams. If the hopes and dreams become real, you will be well paid.
The two major worries I'd have were I long this stock would be Bristol kicking them, and Folkman's penchant for self promotion. Sure, it's possible that Bristol made a mistake. But that's not a position that on which I'd want to bet. Usually when I find someone as promotional as Folkman I dismiss their company out of hand. I do find this situation a little different, as it's my impression that Folkman is serving his ego, rather than promoting worthless stocks for cash profits. Still, it could be the latter, and not something on which I'd like to take a chance.
It's a mistake to characterize this company as a done deal either way. I'm not sure why marc ultra thinks that 'most cancer researchers would agree will get a Nobel Prize for his work in tumor angiogenesis.' This drug has by no means been proven in humans, and that's a long row to hoe. I only know one cancer researcher personally, and he's most skeptical of the potential.
Any position in this company other than trading the price swings in the short term is gambling, IMO.
Barb |
